Mifomet (Metformin Hydrochloride, Sitagliptin)

Metformin Hydrochloride and Sitagliptin, the active ingredients in Mifomet, are a biguanide and a DPP‑4 inhibitor presented as oral tablets for oral use. They treat type 2 diabetes mellitus in adult patients. GNH USA supplies Mifomet as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mifomet, a combination of metformin and sitagliptin, is used in the management of type 2 diabetes mellitus.

- Type 2 diabetes mellitus: improves glycemic control when combined with diet and exercise. - Inadequate control on metformin alone: adds a complementary mechanism to lower blood glucose. - Inadequate control on sitagliptin alone: provides additional glucose‑lowering effect through a different pathway.

Mifomet may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools, especially at treatment initiation. - Abdominal discomfort: cramping or pain in the stomach area. - Headache: transient mild headache. - Hypoglycemia (when used with sulfonylureas or insulin): low blood sugar episodes. - Metallic taste: transient alteration in taste perception.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic condition. - Pancreatitis: inflammation of the pancreas presenting with severe abdominal pain. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes or liver injury. - Renal impairment: worsening kidney function, especially in dehydration. - Severe hypoglycemia: prolonged low blood glucose requiring medical intervention.

Before prescribing Mifomet, clinicians should evaluate patient-specific risk factors and monitor for adverse events. - Renal function assessment: ensure adequate kidney function before initiation. - Hepatic function monitoring: avoid in patients with significant liver disease. - Contraindicated in severe renal impairment: do not use when eGFR is below the recommended threshold. - Monitor for signs of lactic acidosis: educate patients on symptoms. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at room temperature: keep in the original pack, protect from moisture.

Mifomet can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Alcohol: increases risk of lactic acidosis when combined with metformin. - Iodinated contrast agents: may precipitate acute renal failure, requiring temporary discontinuation. - Cimetidine: can raise metformin plasma concentrations, increasing toxicity risk.

Moderate Interactions (Monitor Closely): - Sulfonylureas: heightened risk of hypoglycemia; dose adjustments may be needed. - Rifampin: may reduce sitagliptin exposure, decreasing efficacy. - Diuretics: can affect renal clearance of metformin, requiring monitoring.